Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy

被引:2
|
作者
He, Shuiqing [1 ]
Wu, Yan-Ling [2 ,3 ,5 ,6 ]
Gao, Yongxiang [4 ]
He, Danjie [1 ]
Huang, Ying [1 ]
机构
[1] Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[4] Guangzhou Tianpeng Technol Co Ltd, Dept Data Min & Anal, Guangzhou, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Natl Canc Ctr, Natl Clin Res Canc Ctr, Shenzhen 518116, Guangdong, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen 518116, Guangdong, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 09期
关键词
concurrent chemotherapy; elderly; Epstein-Barr virus; induction chemotherapy; nasopharyngeal carcinoma; prognostic nomograms; INTENSITY-MODULATED RADIOTHERAPY; BARR-VIRUS DNA; NECK-CANCER; PHASE-III; SURVIVAL; COMORBIDITY; HEAD; IMPACT; OLDER; CISPLATIN;
D O I
10.1002/cam4.5789
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aims to evaluate the risk stratification among elderly Nasopharyngeal carcinoma (NPC) patients (>= 60 years old) and select the beneficiaries from concurrent chemotherapy (CCRT) combined with induction chemotherapy (IC). Materials and Methods: A total of 909 elderly non-metastatic NPC patients treated with cisplatin- based CCRT or IC + CCRT between January 2007 and December 2016 were included. Prognostic nomograms were generated according to clinical characteristics and serum biomarkers. The survival outcomes of patients treated with CCRT versus IC + CCRT were compared in three well-matched risk groups (high, medium, and low risk) after PSM analysis. Benefit of IC in people older or younger than 70 years and effect of different IC regimens and cycles on prognosis were analyzed. Results: Nomograms of overall survival (OS) (C-index: 0.64, 95% CI, 0.61- 0.89) and disease special survival (DSS) (C-index: 0.65, 95% CI, 0.62- 0.71) showed good prognostic accuracy. The nomogram for DSS included variables of age, gender, ACE, EBV DNA, N stage, and T stage. OS included variables of age, smoking history, ACE, ALB, EBV DNA, N stage, and T stage. The corresponding 5 year OS rates of high, medium and low risk groups were 87.4%, 82.2%, and 60.9%, respectively (p < 0.001), while the 5 year DSS rates were 92.2%, 84.3%, and 69.0%, respectively (p < 0.001). In the high risk group, IC + CCRT led to significantly higher 5 year OS and DSS rate compared with CCRT (5 year OS rate, 73.5% versus 51.8%, p = 0.006; 5 year DSS rate, 81.4% versus 61.3%, p = 0.002). While in the medium and low risk groups, OS and DSS were not significantly different (OS: p = 0.259, 0.186; DSS: p = 0.29, 0.094). Subgroup analysis showed in the high risk group, only people younger than 70 years old could benefit from IC. TPF and IC cycles of three could lead to the best survival results. Conclusion: Compared with CCRT, OS, and DSS among high risk elderly patients were significantly improved by the addition of IC in patients younger than 70 years old. TPF and three IC cycles were recommended.
引用
收藏
页码:10536 / 10552
页数:17
相关论文
共 50 条
  • [41] Development and application of a serious adverse events risk model for concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
    Li, Jiahui
    Liu, Qianwen
    Qin, Huiying
    MEDICINE, 2024, 103 (34)
  • [42] Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era
    Su, Zhen
    Zou, Guo-rong
    Tang, Jie
    Li, Xiu Yue
    Xie, Fang-Yun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 201 - 211
  • [43] Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2–3-positive nasopharyngeal carcinoma patients
    Hao-Yun Tao
    Hui Liu
    Fang He
    Cai-Xian He
    Ran Li
    Kun-Peng Du
    Ya-Wei Yuan
    Rong-Hui Zheng
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2959 - 2969
  • [44] Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA after Induction Chemotherapy
    Kong, Fangfang
    Pan, Guangsen
    Du, Chengrun
    Hu, Chaosu
    Ying, Hongmei
    CANCERS, 2023, 15 (06)
  • [45] Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial
    Li, Wen-Fei
    Chen, Nian-Yong
    Zhang, Ning
    Hu, Guo-Qing
    Xie, Fang-Yun
    Sun, Yan
    Chen, Xiao-Zhong
    Li, Jin-Gao
    Zhu, Xiao-Dong
    Hu, Chao-Su
    Xu, Xiang-Ying
    Chen, Yuan-Yuan
    Hu, Wei-Han
    Guo, Ling
    Mo, Hao-Yuan
    Chen, Lei
    Mao, Yan-Ping
    Sun, Rui
    Ai, Ping
    Liang, Shao-Bo
    Long, Guo-Xian
    Zheng, Bao-Min
    Feng, Xing-Lai
    Gone, Xiao-Chang
    Li, Ling
    Shen, Chun-Ying
    Xu, Jian-Yu
    Guo, Ying
    Chen, Yu-Ming
    Zhang, Fan
    Lin, Li
    Tang, Ling-Long
    Liu, Meng-Zhong
    Ma, Jun
    Sun, Ying
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 295 - 305
  • [46] Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Jianyuan Zhang
    Shaojun Chen
    Guisheng Li
    Weihua Zhang
    Tingting Qin
    Ping Yin
    Haixin Huang
    Hongwei Jiang
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 1087 - 1097
  • [47] A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma
    Peng, Liang
    Chen, Yu-Pei
    Xu, Cheng
    Tang, Ling-Long
    Chen, Lei
    Lin, Ai-Hua
    Liu, Xu
    Sun, Ying
    Ma, Jun
    ORAL ONCOLOGY, 2018, 86 : 258 - 265
  • [48] Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis
    Li, Haiwen
    Wu, Qibiao
    Luo, Haiqing
    Wu, Jiayuan
    Su, Wenmei
    Yu, Lili
    MEDICINE, 2025, 104 (03)
  • [49] A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma
    Chen, Y. P.
    Wang, Z. X.
    Chen, L.
    Liu, X.
    Tang, L. L.
    Mao, Y. P.
    Li, W. F.
    Lin, A. H.
    Sun, Y.
    Ma, J.
    ANNALS OF ONCOLOGY, 2015, 26 (01) : 205 - 211
  • [50] Concurrent chemotherapy using taxane plus cisplatin versus cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy
    Zhang, Ya-Ni
    Chen, Yu-Pei
    Li, Ji-Bin
    Lu, Tai-Xiang
    Han, Fei
    Chen, Chun-Yan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15